Cosentyx May Increase Risk for Inflammatory Bowel Disease, Italian Researchers Say

Cosentyx May Increase Risk for Inflammatory Bowel Disease, Italian Researchers Say
Italian researchers are calling attention to what they say is an alarming number of newly diagnosed cases of inflammatory bowel disease (IBD) in people treated with the human monoclonal antibody Cosentyx (secukinumab). Their report was published in an open letter to the editor in the The American Journal of Gastroenterology, titled “New Onset of Inflammatory Bowel Disease in

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *